Does Rallies show Form 4 insider transactions for ORIC?

Yes. Rallies tracks ORIC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ORIC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ORIC. It does not provide personalized investment advice.

ORIC (Oric Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Oric Pharmaceuticals, Inc. Common Stock (ORIC) is a publicly traded Healthcare sector company. As of May 21, 2026, ORIC trades at $8.44 with a market cap of $820.89M and a P/E ratio of -5.61. ORIC moved +5.52% today. Year to date, ORIC is +3.19%; over the trailing twelve months it is +48.32%. Its 52-week range spans $3.90 to $14.93. Analyst consensus is strong buy with an average price target of $20.89. Rallies surfaces ORIC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ORIC stock inside the company?

Recent ORIC insider activity includes Piscitelli Dominic sold 52.00K, Heyman Richard A. sold 3.50K, Heyman Richard A. sold 3.20K, Multani Pratik S sold 10.72K, and Piscitelli Dominic sold 10.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ORIC Key Metrics

Key financial metrics for ORIC
Metric	Value
Price	$8.44
Market Cap	$820.89M
P/E Ratio	-5.61
EPS	$-1.47
Dividend Yield	0.00%
52-Week High	$14.93
52-Week Low	$3.90
Volume	217
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-129.47M
Gross Margin	0.00%

Recent ORIC Insider Trades

Piscitelli Dominic sold 52.00K (~$702.69K) on Feb 24, 2026.
Heyman Richard A. sold 3.50K (~$42.02K) on Jan 16, 2026.
Heyman Richard A. sold 3.20K (~$38.41K) on Jan 16, 2026.
Multani Pratik S sold 10.72K (~$97.13K) on Dec 16, 2025.
Piscitelli Dominic sold 10.72K (~$97.13K) on Dec 16, 2025.

Latest ORIC News

ORIC selects 400 mg rinzimetostat dose for Phase 3 after 93% rPFS; $420M runway — May 4, 2026
Rinzimetostat Inhibits PRC2 in Over 1,100 Samples, Enhances CSPC/CRPC Response — Apr 17, 2026
ORIC selects 400 mg RP3D of rinzimetostat, shows 84% five-month rPFS — Mar 31, 2026
ORIC’s Rinzimetostat Shows Best-in-Class Preclinical Efficacy in Resistant Prostate Cancer Models — Mar 17, 2026
JPMorgan Maintains Overweight on Oric Citing 55% PSA50 Response and Phase 3 Timeline — Mar 10, 2026

ORIC Analyst Consensus

11 analysts cover ORIC: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.89.

Common questions about ORIC

Who is trading ORIC stock inside the company?: Recent ORIC insider activity includes Piscitelli Dominic sold 52.00K, Heyman Richard A. sold 3.50K, Heyman Richard A. sold 3.20K, Multani Pratik S sold 10.72K, and Piscitelli Dominic sold 10.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ORIC?: Yes. Rallies tracks ORIC insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ORIC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ORIC. It does not provide personalized investment advice.